An Update on Medications for Brain Arteriovenous Malformations

Area of Science:

• Neurology
• Vascular Biology
• Pharmacology

Background:

• Brain arteriovenous malformations (bAVMs) pose significant hemorrhage risks despite existing treatments.
• In vitro studies enhance understanding of bAVM development, growth, and rupture mechanisms.

Purpose of the Study:

• To review current medication development for bAVMs.
• To highlight potential future applications of these novel therapies.

Main Methods:

• Review of in vitro investigations and clinical trial data.
• Analysis of therapeutic targets including angiogenic pathways, blood-brain barrier integrity, and matrix metalloproteinase activity.

Main Results:

• Bevacizumab targets the VEGF angiogenic pathway.
• Thalidomide/lenalidomide address blood-brain barrier impairment.
• Doxycycline targets matrix metalloproteinase overexpression.

Conclusions:

• Emerging drug therapies offer new hope for treating complex bAVMs.
• Further research and clinical trials are essential for validating these promising treatments.